ReviewF1000Research2020
A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies.
Review in F1000Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Risk factors for acute kidney injury in Chinese patients with lupus nephritis: a meta-analysis.BMC nephrology · 2026Pooled it
- Successful Cyclosporine Salvage Therapy in Refractory Lupus Nephritis: A Case Study From Ethiopia.Current therapeutic research, clinical and experimental · 2026Article
- The Evolution of Lupus Nephritis Therapy from the 1960s to the Present.Bioengineering (Basel, Switzerland) · 2026Review
- Mechanistic study of compound Muniziqi granule on lupus nephritis in MRL/lpr mice: insights from transcriptomics and experimental validation.Lupus science & medicine · 2026Article
- Telitacicept as a New Therapeutic Avenue for Generalized Myasthenia Gravis and Thymoma-Associated Myasthenia Gravis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Article
- Identification of novel biomarkers for lupus nephritis.Biomolecules & biomedicine · 2025Article
- Telitacicept as double-targeted therapy for myasthenia gravis coexisting with connective tissue disease: three case reports.Frontiers in immunology · 2025Article
- Post-marketing safety surveillance of voclosporin: an observational, pharmacovigilance study leveraging faers database study on the safety of voclosporin.Frontiers in pharmacology · 2025Article
- Review
- Autoimmune Responses and Therapeutic Interventions for Systemic Lupus Erythematosus: A Comprehensive Review.Endocrine, metabolic & immune disorders drug targets · 2024Review
- Experience with abatacept in refractory lupus nephritis.Rheumatology international · 2023Review
- Characterization of Serum Cytokine Profiles of Patients with Active Lupus Nephritis.International journal of molecular sciences · 2023Article
- Recent advances in immunotherapies for lupus nephritis.Pediatric nephrology (Berlin, Germany) · 2023Review
- Complement as a Biomarker for Systemic Lupus Erythematosus.Biomolecules · 2023Review
- Relationship of complement activation pathway to clinical and pathological characteristics and renal outcome in patients with lupus nephritis.Zeitschrift fur Rheumatologie · 2022Article
- Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?International journal of molecular sciences · 2022Review
- GBP2 acts as a member of the interferon signalling pathway in lupus nephritis.BMC immunology · 2022Article
- Glomerular Expression of S100A8 in Lupus Nephritis: An Integrated Bioinformatics Analysis.Frontiers in immunology · 2022Article
- Correlations of peripheral blood neutrophil-lymphocyte ratio and lymphocyte-monocyte ratio with renal function and prognosis in patients with lupus nephritis.American journal of translational research · 2022Article
- Telitacicept: First Approval.Drugs · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupus nephritis is an important cause of both acute kidney injury and chronic kidney disease that can result in end-stage renal disease. Its pathogenic mechanisms are characterized by aberrant activation of both innate and adaptive immune responses, dysregulation of inflammatory signaling pathways, and increased cytokine production. Treatment of lupus nephritis remains a challenging issue in the management of systemic lupus erythematosus since the clinical presentation, response to treatment, and prognosis all vary considerably between patients and are influenced by ethnicity, gender, the degree of chronic kidney damage, pharmacogenomics, and non-immunological modulating factors. Elucidation of the various immunopathogenic pathways in lupus nephritis has resulted in the development of novel therapies, including biologics that target specific antigens on B lymphocytes to achieve B cell depletion, agents that modulate B cell proliferation and development, drugs that block co-stimulatory pathways, drugs that target T lymphocytes primarily, and therapies that target complement activation, signaling pathways, pro-inflammatory cytokines, and neutrophil extracellular traps. This review will discuss recent advances in the understanding of disease pathogenesis in lupus nephritis in the context of potential emerging therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.